Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.59 |
| ▸ | MAPT | P10636 | 8/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22485788 | 1.00 | HCAR2 (0.59) | HCAR2MAPTMEN1NPC1MAPK1 | |
| SCHEMBL8694166 | 1.00 | HCAR2 (0.59) | HCAR2MAPTMEN1NPC1MAPK1 | |
| Diethyl Maleate SCHEMBL2015895 | 0.83 | HCAR2 (0.80) | HCAR2MAPTLMNAMDM2ATM | |
| Diethyl Maleate SCHEMBL43033 | 0.83 | HCAR2 (0.80) | HCAR2MAPTLMNAMDM2ATM | |
| Diethyl Maleate SCHEMBL27966383 | 0.83 | HCAR2 (0.80) | HCAR2MAPTLMNAMDM2ATM | |
| Diethyl Maleate SCHEMBL2015896 | 0.83 | HCAR2 (0.80) | HCAR2MAPTLMNAMDM2ATM | |
| Diethyl Maleate SCHEMBL42602 | 0.83 | HCAR2 (0.80) | HCAR2MAPTLMNAMDM2ATM | |
| SCHEMBL18406963 | 0.83 | HCAR2 (0.62) | HCAR2MAPTMEN1NPC1MAPK1 | |
| Diethyl Maleate SCHEMBL60423 | 0.83 | HCAR2 (0.80) | HCAR2MAPTLMNAMDM2ATM | |
| Diethyl Maleate SCHEMBL135447 | 0.81 | HCAR2 (0.76) | HCAR2MAPTLMNAMDM2ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49687-E1 | Thienopyrimidine and thienopyridine compounds and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230212183-A9 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230212170-A1 | INHIBITORS OF KRAS G12C PROTEIN AND USES THEREOF | ANTENGENE DISCOVERY LIMITED (CN) | 2023-07-06 | — | — | US | disclosed |
| US-11673898-B2 | Substituted inhibitors of menin-MLL and methods of use | KURA ONCOLOGY, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230147053-A1 | FUSED N-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2023-05-11 | — | — | US | disclosed |
| US-11639346-B2 | Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS | ARAXES PHARMA LLC (US) | 2023-05-02 | — | — | US | disclosed |
| US-20180194748-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2018-07-12 | — | — | US | disclosed |
| US-10011600-B2 | Methods and compositions for inhibition of Ras | ARAXES PHARMA LLC (US) | 2018-07-03 | — | — | US | disclosed |
| US-20180155348-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC | 2018-06-07 | — | — | US | disclosed |
| US-9982011-B2 | Legumain activated doxorubicin derivative as well as preparation method and application thereof | YAFEI (SHANGHAI) BIOPHARMACEUTICAL CO., LTD. (CN) | 2018-05-29 | — | — | US | disclosed |
| US-20160108019-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC | 2016-04-21 | — | — | US | disclosed |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2015-08-27 | — | — | US | disclosed |
| US-5846941-A | Isosteric antiherpes peptide derivatives II | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 1998-12-08 | — | — | US | disclosed |
| EP-0560267-B1 | Isosteric antiherpes peptide derivatives | BOEHRINGER INGELHEIM CA LTD (CA) | 1998-08-19 | — | — | EP | disclosed |
| EP-0767671-A1 | METHOD OF COMBATING ACYCLOVIR-RESISTANT HERPES SIMPLEX VIRAL INFECTIONS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 1997-04-16 | — | — | EP | disclosed |
| US-5574015-A | Isosteric antiherpes peptide derivatives | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1996-11-12 | — | — | US | disclosed |
| CN-1126438-A | Method of combating acyclovir-resistant herpes simplex viral infections | BIO MEGA BOEHRINGER INGELHEIM (CA) | 1996-07-10 | — | — | CN | disclosed |
| WO-1994025046-A1 | METHOD OF COMBATING ACYCLOVIR-RESISTANT HERPES SIMPLEX VIRAL INFECTIONS | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1994-11-10 | — | — | WO | disclosed |
| WO-1993018056-A1 | ISOSTERIC ANTIHERPES PEPTIDE DERIVATIVES | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1993-09-16 | — | — | WO | disclosed |
| EP-0560267-A1 | Isosteric antiherpes peptide derivatives | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1993-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155348-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | KRAS, NRAS, HRAS | HCAR2 4031/4885MAPT 251/4885MEN1 163/4885 |
| US-20180194748-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | HCAR2 3423/4885MAPT 4598/4885MEN1 170/4885 |
| US-20160108019-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | KRAS, NRAS, HRAS | HCAR2 3779/4885MAPT 172/4885MEN1 102/4885 |
| US-20230147053-A1 | FUSED N-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | HCAR2 2150/4885MAPT 4151/4885MEN1 230/4885 |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | HCAR2 4029/4885MAPT 279/4885MEN1 138/4885 |
| US-11639346-B2 | Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS | KRAS, NRAS, HRAS | HCAR2 2257/4885MAPT 4060/4885MEN1 132/4885 |
| US-20230212183-A9 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | HCAR2 4029/4885MAPT 279/4885MEN1 138/4885 |
| US-20230212170-A1 | INHIBITORS OF KRAS G12C PROTEIN AND USES THEREOF | KRAS, NRAS, HRAS | HCAR2 4452/4885MAPT 3275/4885MEN1 847/4885 |
| US-11673898-B2 | Substituted inhibitors of menin-MLL and methods of use | MLLT1, MEN1, MLLT3 | HCAR2 3764/4885MAPT 2699/4885MEN1 2/4885 |
| US-10011600-B2 | Methods and compositions for inhibition of Ras | KRAS, NRAS, HRAS | HCAR2 4740/4885MAPT 3744/4885MEN1 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.